Project cooperationUpdated on 15 October 2026

Horizon Europe Health 2027: Impact, Exploitation and Healthcare Innovation Uptake Partner

Managing Director at Nexuswelt Group - EU Funding and Innovation Agency

München, Germany

About

Nexuswelt Group, operating through Germany and Cyprus, is seeking to join Horizon Europe Cluster 1 Health 2027 consortia as an active implementation, exploitation and impact partner.

Our proposed contributions include:

Stakeholder engagement involving healthcare professionals, patients, industry and relevant organisations.
Human-centred technology acceptance and user engagement for digital health and medical innovations.
Exploitation strategies, business-case development and pathways to market and healthcare adoption.
Communication, dissemination, training and capacity building.
Impact assessment, KPI frameworks and sustainability planning.

We are looking to collaborate with universities, research institutes, hospitals, healthcare providers, medtech and digital health companies preparing collaborative Horizon Europe Health proposals.

Our objective is to take responsibility for clearly defined project activities that help translate research and technological innovation into practical, measurable benefits for healthcare systems and end users.

We are particularly interested in consortia where stakeholder engagement, real-world adoption, exploitation and implementation are integral to the project’s expected impact.

Topic

Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases

Type

Partner seeks Consortium/Coordinator

Organisation

Nexuswelt Group - EU Funding and Innovation Agency

Company (SME)

Munich, Germany

Similar opportunities

Project cooperation
Implementation Intelligence for Product Development and Market Introduction
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Reda Sadki
Executive director at The Geneva Learning Foundation
Geneva, Switzerland
Project cooperation
Turning healthcare innovation into real-world impact.
- Consortium/Coordinator seeks Partners
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Anna Lackner
Managing Director at Nexuswelt Group - EU Funding and Innovation Agency
München, Germany
Project cooperation
Turn your innovative ideas into impactful projects with Italbiotec
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Melissa Balzarotti
Head of Life Science Project Management Unit at Italbiotec
Milano, Italy